.Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01C_HypothalamicHormones.H01CC03_Elagolix.Elagolix

Information

Elagolix is a non-peptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist used primarily for the management of moderate to severe pain associated with endometriosis in women. It is approved by the FDA for this indication.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy premenopausal women following oral administration.

References

1. Shebley, M, et al., & Mostafa, NM (2020). Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis. Clinical pharmacokinetics 59(3) 297–309. DOI:10.1007/s40262-019-00840-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31749075

2. Zhang, X, et al., & Wen, Q (2024). Development and Application of a Physiologically Based Pharmacokinetic Model for Elagolix in the Adult and Adolescent Population. Clinical pharmacokinetics 63(9) 1357–1370. DOI:10.1007/s40262-024-01402-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39060899

3. Abbas Suleiman, A, et al., & Mostafa, NM (2020). Exposure-Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis-Associated Pain. CPT: pharmacometrics & systems pharmacology 9(11) 639–648. DOI:10.1002/psp4.12560 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32945631

Revisions

• 06/2025 initial generated model